언어 선택

DDC

DDC 분자 정보

영어 이름	Aromatic-L-amino-acid decarboxylase	시판 약물 수	8
임상 약물 수	12	표적 별명	EC:4.1.1.28，EC 4.1.1，DDC，AADC，Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase)，Aromatic-L-Amino-Acid Decarboxylase，Aromatic L-Amino Acid Decarboxylase，EC 4.1.1.28，DOPA decarboxylase
최고 연구 개발 단계	Approved

영어 이름	Aromatic-L-amino-acid decarboxylase
표적 별명	EC:4.1.1.28，EC 4.1.1，DDC，AADC，Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase)，Aromatic-L-Amino-Acid Decarboxylase，Aromatic L-Amino Acid Decarboxylase，EC 4.1.1.28，DOPA decarboxylase
시판 약물 수	8
임상 약물 수	12
최고 연구 개발 단계	Approved

DDC 제품 목록

속성
Protein (1)
제품 라이브러리
온라인 (1)
종
Human (1)
태그
His Tag (1)
마커
Unconjugated (1)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
DDC-H55H6	Human	InsectCells	Human DDC / Dopa Decarboxilase Protein, His Tag (MALS verified)

총 수량1

DDC분자 배경

Dopa decarboxilase (DDC), also known as aromatic amino acid decarboxylase, is a group II decarboxylase. The enzyme catalyzes the decarboxylation of aromatic L-amino acids to produce the corresponding amines. DDC produces the neurotransmitters dopamine and serotonin from L-Dopa and L-5-hydroxytryptophan, respectively. DDC inhibitors is in clinical use to treat Parkinson's disease(PD), usually co-administrated with L-DOPA. DDC would block peripheral conversion to dopamine and allow a greater percentage of L-DOPA to reach the brain, causing an increase in brain dopamine levels, and reducing the side effects of dopamine-rich blood.

DDC분자 별명

Aromatic-L-amino-acid decarboxylase,Dopa decarboxilase,AADC

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
VGN-R09	VGN-R09b; VGN-R09	Phase 3 Clinical	Shanghai Vitalgen BioPharma Co Ltd	Aromatic amino acid decarboxylase deficiency; Parkinson Disease	상세
Levodopa/Carbidopa (Hengrui Medicine)	HRG-2010	Phase 3 Clinical	Jiangsu Hengrui Medicine Co Ltd	Parkinson Disease	상세
Buspirone/Carbidopa/Levodopa		Phase 2 Clinical	Universite Laval	Multiple Sclerosis; Spinal Cord Injuries	상세
Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical)	WD-1905	Phase 2 Clinical	Shanghai WD Pharmaceutical Co Ltd	Parkinsonian Disorders	상세
Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical)	WD-1603	Phase 2 Clinical	Shanghai WD Pharmaceutical Co Ltd	Parkinson Disease; Parkinsonian Disorders	상세
Ezaladcigene resoparvovec	VY-AADC; VY-AADC01; GZ-404477; AV-201; VY-AADC02	Phase 1 Clinical	University Of California, Voyager Therapeutics Inc	Aromatic amino acid decarboxylase deficiency; Parkinson Disease	상세
AAV2-hAADC gene therapy (UCSF)		Phase 1 Clinical	University Of California San Francisco		상세
Levodopa/Carbidopa (Contera Pharma)	JM-012; CP-012; SOL-707	Phase 1 Clinical	Contera Pharma	Parkinson Disease	상세
RGL-193	RGL-193	Phase 1 Clinical	Shanghai Regenelead Therapies Co Ltd	Parkinson Disease	상세
Carbidopa/oxytriptan	EVX-101	Phase 1 Clinical	Evecxia Therapeutics Inc	Depression; Depressive Disorder	상세
Levodopa/Carbidopa granule(WD Pharmaceutical)	WD-2010	Phase 1 Clinical	Shanghai WD Pharmaceutical Co Ltd	Parkinsonian Disorders	상세
Levodopa/Carbidopa(WD Pharmaceutical)	WD-1804	Phase 1 Clinical	Shanghai WD Pharmaceutical Co Ltd	Parkinsonian Disorders	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Levodopa/Benserazide Hydrochloride		Approved	F. Hoffmann-La Roche Ltd	Madopar	Switzerland	Parkinson Disease	F. Hoffmann-La Roche Ltd	1973-06-27	Parkinson Disease	상세
Eladocagene exuparvovec	PTC-AADC	Approved	National Taiwan University, Ptc Therapeutics Inc	KEBILIDI, Upstaza	EU	Amino Acid Metabolism, Inborn Errors	Ptc Therapeutics International Ltd	2022-07-18	Amino Acid Metabolism, Inborn Errors; Aromatic amino acid decarboxylase deficiency	상세
Levodopa/Carbidopa	DM-1992; AP-CDLD; TPI-926; ND-0612H; PW-4153; LCIG; ABT-SLV187; IPX-203; INP-107(POD™ carbidopa/levodopa); IPX-066; ABT-SLV-187; AP-09004; AP-CD/LD; ND-0612; ND-0680; ND-0612L; IPX-054	Approved	Merck Sharp & Dohme Corp	Patrome, DopaFuse, Sinemet, Numient, Menesit, Duodopa, Vadova, Rytary, Isicom, Duopa, Flexilev, CREXONT, Nacom (imciromab), Nacom retard, Parcopa	United States	Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary	Organon	1975-05-02	Albinism; Albinism, Oculocutaneous; Amblyopia; Amyotrophic Lateral Sclerosis; Aphasia, Broca; Cocaine-Related Disorders; Cognition Disorders; Depressive Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Diabetes Mellitus; Diabetic Retinopathy; Gait Apraxia; Motor Neuron Disease; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Parkinsonian Disorders; Stroke	상세
Benserazide Hydrochloride	Ro-4-4602	Approved			Mainland China	Parkinson Disease; Dyskinesias	Shanghai Yishengyuan Pharmaceutical Co Ltd	1995-01-01	Anemia, Sickle Cell; beta-Thalassemia; Dyskinesias; Parkinson Disease	상세
Foslevodopa/Foscarbidopa	ABBV-951	Approved	Abbvie Inc	VYALEV, Vyalev, Produodopa	Romania, Cyprus, Belgium	Parkinson Disease	Abbvie Deutschland Gmbh & Co Kg, Abbvie Inc, Abbvie Sa		Parkinson Disease	상세
Carbidopa/Entacapone/Levodopa	ELC-200; ODM-101	Approved	Orion Pharma	Stalevo, LECIGon, Trigel, LECIGel, 达灵复	United States	Parkinson Disease	Orion Pharma A/S	2003-06-11	Parkinson Disease	상세
Carbidopa	MK-486	Approved		Lodosyn	United States	Parkinson Disease	Aton	1977-04-25	Orthostatic Intolerance; Parkinson Disease; Postural Orthostatic Tachycardia Syndrome	상세
Carbidopa/Melevodopa	V-1512; GT-1512; CHF-1512; CNP-1512	Approved	Chiesi Farmaceutici SPA	Sirio	Italy	Parkinson Disease	null	2003-01-01	Parkinson Disease	상세